
FDA accepts Orvida Pharma's KM-023 into Rare Disease Evidence Principles process for Olmsted syndrome
Orvida Pharma announced that the FDA has accepted its lead drug candidate KM-023 (ontivatrep) into the Rare Disease Evidence Principles (RDEP) process for treating Olmsted syndrome, a rare genetic skin disorder. This acceptance allows Orvida to engag...





